Okay, let's tackle this question. The patient has Crohn's disease, which is an inflammatory bowel disease. He's on immunosuppressive therapy, and now he developed TB reactivation. The question is asking which immunosuppressant is most likely responsible.

First, I need to recall the common immunosuppressants used in Crohn's. The standard ones include corticosteroids, thiopurines like azathioprine, methotrexate, and biologics like TNF-alpha inhibitors (e.g., infliximab, adalimumab). Also, maybe something like cyclosporine or tacrolimus.

TB reactivation is a known complication of immunosuppressive therapy. The key here is that TB reactivation is more likely with agents that significantly suppress cell-mediated immunity. TNF-alpha inhibitors are particularly notorious for this. TNF-alpha is part of the immune response against TB, so blocking it can reactivate latent TB.

Corticosteroids can also suppress immunity but are more associated with general immunosuppression rather than specific TB reactivation. Thiopurines and methotrexate might contribute but are less commonly linked to TB compared to TNF inhibitors.

So among the options, the biologics, especially TNF-alpha inhibitors, are the most likely culprits here. The correct answer would be the TNF-alpha inhibitor, which is option C or D, depending on the options given. Since the options aren't listed here, but assuming the answer is a TNF inhibitor, the explanation should focus on their mechanism.

**Core Concept**
The reactivation of tuberculosis (TB) in immunosuppressed patients is primarily linked to therapies that impair cell-mediated immunity, particularly agents targeting tumor necrosis factor-alpha (TNF-α). TNF-α is critical for granuloma formation and containment of *Mycobacterium tuberculosis*.

**Why the Correct Answer is Right**
TNF-α inhibitors (e.g., infliximab, adalimumab) are potent immunosuppressants used in Crohn’s disease. By blocking TNF-α, these drugs disrupt the immune response against intracellular pathogens like TB. This leads to granuloma destabilization and reactivation of latent TB, especially in patients with prior exposure. Their mechanism directly impairs macrophage function and cytokine signaling essential for TB control.

**Why Each Wrong Option is Incorrect**
**Option A:** Corticosteroids suppress inflammation but are not the primary cause of TB reactivation compared to TNF-α inhibitors. They are less specific in targeting TB-related immune pathways.
**Option B:** Thiopurines (e.g., azathioprine) inhibit purine synthesis in lymphocytes, reducing immune activity but not as profoundly as TNF-α inhibitors. TB reactivation is rare but possible.
**Option D:** Methotrexate antagonizes folate metabolism, primarily affecting rapidly dividing cells. While it increases infection risk, TB reactivation is less common than with TNF-α inhibitors.

**Clinical Pearl / High-Yield Fact**
Before initiating TNF-α inhibitors, all patients must undergo TB screening (e.g., QuantiFERON-TB Gold, chest X-ray). Reactivation risk is highest within the first 3–12 months of therapy, making prophylactic anti-TB treatment

✓ Correct Answer: B. Infliximab